Skip to main content
    E

    Entrada Therapeutics Inc (TRDA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.00
    -0.09 (-1.77%)

    Market Cap: $199.28M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Entrada Therapeutics Inc (TRDA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Entrada Therapeutics reported revenue of $25.42M for the fiscal year ended Dec 31, 2025, down 87.9% from the year before. That year, net income was -$143.75M with a net margin of -565.5%, operating cash flow was -$128.51M and free cash flow was -$129.55M. The quarter ended Sep 30, 2026 had revenue of $905.00K and net income of -$39.74M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$25.42M-87.9%100.0%-621.1%-565.5%
    Dec 2024$210.78M+63.4%100.0%22.3%31.1%
    Dec 2023$129.01MN/A100.0%-2.5%-5.2%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$25.42M$210.78M$129.01M$0$0$0$0
    Cost of revenue$0$0$0$0$0$0$104.00K
    Gross profit$25.42M$210.78M$129.01M$0$0$0-$104.00K
    Research and development$142.27M$125.31M$99.88M$66.61M$35.93M$21.10M$8.22M
    Operating income-$157.90M$47.01M-$3.16M-$97.25M-$51.13M-$26.67M-$11.82M
    Net income-$143.75M$65.63M-$6.68M-$94.62M-$51.16M-$26.52M-$4.65M
    EBITDA-$157.47MN/A$9.12M-$92.57M-$50.04M-$26.20M-$11.72M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$905.00K$898.00K$875.00K$1.30M$1.61M$1.95M$20.56M$37.40M$19.57M$94.69M$59.12M$41.85M
    Gross profit$905.00K$898.00K$875.00K$1.30M$1.61M$1.95M$20.56M$37.40M$19.57M$94.69M$59.12M$41.85M
    Operating income-$41.69M-$44.96M-$42.30M-$42.21M-$47.05M-$46.85M-$21.79M-$5.87M-$21.66M$53.42M$21.11M$4.91M
    Net income-$39.74M-$42.76M-$39.72M-$39.16M-$44.13M-$43.10M-$17.35M$1.13M-$14.03M$55.03M$23.50M-$9.54M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $4.14M by $86.26M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$377.38M$526.32M$469.19M$252.06M$305.83M$43.53M$18.24M
    Current assets$306.25M$440.04M$369.77M$209.88M$298.70M$39.95M$17.44M
    Cash and equivalents$90.39M$101.21M$67.60M$45.16M$291.06M$39.05M$16.84M
    Total liabilities$71.25M$97.64M$226.83M$39.50M$7.12M$3.36M$33.76M
    Short-term debt$4.14M$7.56M$7.91M$8.41MN/AN/AN/A
    Shareholder equity$306.13M$428.68M$242.36M$212.55M$298.72M-$41.49M-$15.52M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$266.88M$298.88M$335.52M$377.38M$412.90M$448.78M$486.48M$526.32M$554.59M$581.96M$510.84M$469.19M
    Total liabilities$68.56M$65.47M$64.66M$71.25M$72.18M$69.28M$69.22M$97.64M$132.14M$152.04M$241.48M$226.83M
    Cash and equivalents$112.24M$99.28M$76.44M$90.39M$93.29M$72.48M$67.84M$101.21M$78.05M$185.25M$68.44M$67.60M
    Shareholder equity$198.32M$233.41M$270.85M$306.13M$340.72M$379.50M$417.26M$428.68M$422.45M$429.93M$269.37M$242.36M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$128.51M-$41.56M$139.80M-$93.79M-$50.86M-$25.57M-$10.80M
    Capital expenditures$1.04M$3.16M$5.61M$2.89M$4.58M$2.32M$630.00K
    Free cash flow-$129.55M-$44.72M$134.19M-$96.67M-$55.44M-$27.89M-$11.43M
    Investing cash flow$116.81M-$27.80M-$138.40M-$148.65M-$4.58M-$2.32M-$630.00K
    Financing cash flow$887.00K$102.96M$21.04M$479.00K$307.46M$50.09M$38.00K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$29.96M-$32.46M-$41.70M-$32.20M-$28.31M-$29.49M-$38.51M-$31.61M-$24.27M$39.83M-$25.52M-$4.01M
    Capital expenditures$161.00K$11.00K$44.00K$207.00K$171.00K$275.00K$1.14M$635.00K$639.00K$1.05M$838.00K$976.00K
    Free cash flow-$30.13M-$32.47M-$41.74M-$32.41M-$28.48M-$29.76M-$39.65M-$32.24M-$24.91M$38.79M-$26.36M-$4.99M
    Last 12 quarters

    Frequently Asked Questions About TRDA

    What is Entrada Therapeutics' annual revenue?

    Entrada Therapeutics reported revenue of $25.42M for the fiscal year ended Dec 31, 2025.

    How fast is Entrada Therapeutics' revenue growing?

    Revenue was down 87.9% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Entrada Therapeutics profitable?

    No. Entrada Therapeutics reported net income of -$143.75M for the fiscal year ended Dec 31, 2025, with a net margin of -565.5%.

    How much free cash flow does TRDA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$128.51M minus capital expenditures of $1.04M produced free cash flow of -$129.55M.

    How much debt does Entrada Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $4.14M and cash and equivalents of $90.39M.